Remove Clinical Development Remove Download Remove Licensing
article thumbnail

Ascentage Pharma’s Licensee UNITY Biotechnology Announces Milestone Reached in Clinical Development of Treatments for Age-Related Disease, Leading to Milestone Payment

The Pharma Data

UBX1325 is developed from BM-962, a Bcl-xL inhibiting compound licensed to UNITY by Ascentage Pharma for the treatment of age-related diseases. This progress in clinical development qualifies Ascentage Pharma for a milestone payment according to the terms of the licensing agreement. SOURCE Ascentage Pharma.

article thumbnail

BioInvent and Cantargia sign manufacturing agreement for monoclonal antibody CAN10

The Pharma Data

technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering. The following files are available for download: View original content: [link].

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Synthetic Biologics Announces Extension of Compliance Plan Period by NYSE American

The Pharma Data

View original content to download multimedia: [link]. . SOURCE Synthetic Biologics, Inc. . Source link.

article thumbnail

Nomination Committee appointed for BioInvent International’s Annual General Meeting 2021

The Pharma Data

technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the company’s own clinical development pipeline or for additional licensing and partnering. The following files are available for download: View original content: [link].

article thumbnail

AhR activators – friend or foe?

Metabolite Tales Blog

Figure 3: Roquinimex (linomide) Clinical development of both laquinimod and roquinimex was halted due to serious cardiovascular events. Studies in non-clinical species raised no obvious red flags of this clinical outcome. Teva Pharmaceuticals licensed laquinimod from Active Biotech. This was unexpected.

article thumbnail

CASI Pharmaceuticals Partner, BioInvent, Presents Phase I/IIA Data That Suggests BI-1206 Restores Activity Of Rituximab In Relapsed Non-Hodgkin’s Lymphoma Patients

The Pharma Data

ET ) to discuss the results and next steps in clinical development of BI-1206. technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.

article thumbnail

Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel

The Pharma Data

AR-301 is a fully human IgG1 mAb currently in Phase 3 clinical development targeting gram-positive Staphylococcus aureus ( S. AR-101 is a fully human immunoglobulin M, or IgM, mAb in Phase 2 clinical development targeting Pseudomonas aeruginosa ( P. View original content to download multimedia: [link].